Consumer Defensive
RBC Life Sciences, Inc.(RBCL)
Live Price
Offline$0.0007
+0.00% today
1Y Change
+600.00%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- โ
- Revenue Growth
- +5.8%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 253 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RBC Life Sciences, Inc. (RBCL) is a Consumer Defensive stock with listed on OTC. The stock last traded around $0.00 and up 600.0% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +5.8%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue +5.8%, EPS 0.0%, free cash flow +100.2% with operating margin -2.6% and ROIC -8.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines RBCL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+5.8% vs +1.7% peer median
Operating Margin
Below sector median
-2.6% vs +6.6% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2017 was reported on Jun 30, 2017, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is +5.8% and EPS is 0.0%, while operating margin sits near -2.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2017 Jun 30, 2017 | โ | +0.0% | +0.0% | +0.0% |
2017 Mar 31, 2017 | โ | +0.0% | +0.0% | +0.0% |
2016 Dec 31, 2016 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RBCL
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RBCL Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RBCL and SPY.
Company Overview
RBC Life Sciences, Inc.
Other OTC
RBC Life Sciences, Inc. manufactures, markets, and distributes nutritional supplements and personal care products in North America, Southeast Asia, and Australia. The company's Nutritional Products segment offers nutritional supplements and personal care products, including herbs, vitamins, and minerals; and natural skin, hair, and body care products through a network of independent distributors and license arrangements. Its products include Stem-Kine, a dietary supplement; Microhydrin and Microhydrin Plus antioxidants; VitAloe, a blend of research-backed ingredients; OliViva, an antioxidant beverage to support immune and cardiovascular system; Organic Spirulina, a nutritious alga that provides range of nutrients and easily digested proteins; and NeuroBright to support brain function, and enhance energy and acuity. This segments products also comprise Colo-Vada Plus, a colon cleansing program; HydraCel to enhance the quality of drinking water; 24 Seven, a multivitamin/mineral supplement; Immune 360 to nourish and support the function of the immune system; and Aloe Gelee gel that provides the soothing and moisturizing. Its Medical Products segment offers wound care products for the treatment and healing of wounds, such as pressure ulcers, leg ulcers, cuts, burns, and abrasions. Its products include cleansers, dressings, hydrogels, collagen, calcium alginates, moisture barriers, antimicrobials, and a hydrogel wound dressing with Lidocaine. This segment also offers other wound care products designed to reduce destruction to skin and tissue caused by radiation; and to reduce pain and itching in the skin, and the internal mucosa caused by radiation reactions or reactions to various cancer medications. This segment sells its products under the MPM Medical brand to hospitals, nursing homes, clinics, and pharmacies through a network of medical/surgical supply dealers and pharmaceutical distributors. The company was founded in 1988 and is headquartered in Irving, Texas.
- Leadership
- David Price
- IPO Date
- Jan 3, 2000
- Employees
- 89
- Street Address
- 2301 Crown Court
- Mailing
- Irving, TX, 75038
- Region
- Irving, TX, US
- Reporting Currency
- USD
- Investor Line
- 972 893 4000
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 5.8
- Price/Sales
- 0.0
- Price/Book
- 0.0
Growth
- Revenue
- +5.8%
- EPS
- 0.0%
- Free Cash Flow
- +100.2%
Profitability
- Gross Margin
- 52.8%
- Operating Margin
- -2.6%
- Net Margin
- -2.9%
- ROE
- -10.1%
- ROIC
- -8.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.28
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.